Attorney General Raoul urges Federal
Government action to increase access and affordability for drug to
treat COVID-19
Remdesivir is an Anti-Viral Drug Showing
Promising Results for Those Hospitalized Due to COVID-19
Send a link to a friend
[September 11, 2020]
Attorney General Kwame Raoul today joined a
bipartisan coalition of 34 attorneys general in sending a letter
request to the U.S. Department of Health and Human Services (HHS),
the National Institutes of Health (NIH), and the Food and Drug
Administration (FDA), urging them to use their legal authority under
the Bayh-Dole Act to increase the availability of remdesivir.
Remdesivir, a drug manufactured by Gilead Sciences, Inc. (Gilead),
has shown promising results in reducing mortality and
hospitalizations from COVID-19.
|
“COVID-19 has claimed thousands of lives in
Illinois and tens of thousands of lives across the nation.
Remdesivir has shown promising results in treating those
hospitalized due to COVID-19, and no one should be denied access to
treatment due to the cost of the drug” Raoul said. “I urge the
federal government to use its authority to ensure that this
potentially lifesaving drug is available and affordable for all who
need it.”
Remdesivir is an FDA fast-tracked antiviral drug that was produced
with the benefit of millions of dollars of federal funding and the
time and expertise of CDC and military scientists. Despite the
substantial federal funding provided to its manufacturer, Gilead has
been unable to assure a supply of remdesivir sufficient to alleviate
the health and safety needs of the country amid the pandemic.
![](http://archives.lincolndailynews.com/2020/Aug/05/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
As of Aug. 3, 2020, more than 4.64 million Americans have contracted
COVID-19 and 154,000 have died. Yet, by the end of this year, Gilead
is expected to produce only 2 million treatments, or enough
remdesivir to cover about half of the current confirmed COVID-19
patients in the U.S. Before this crisis is over and a vaccine made
available, many more Americans may become sick, and their recovery
may hinge on the availability and affordability of remdesivir.
In the letter, Raoul and the coalition urge the
federal government to exercise its rights under the Bayh-Dole Act,
which allows the NIH and FDA to ensure Americans can afford and have
reasonable access to a sufficient supply of remdesivir during this
pandemic.
[to top of second column] |
![](http://archives.lincolndailynews.com/2020/Aug/05/images/ads/current/graue_20SILVERADO_071320.png)
Despite a manufacturing cost of between $1 and $5,
Gilead has set the price of the drug at an outrageous and
unconscionable $3,200 per treatment course. Under the Bayh-Dole Act,
the NIH and FDA have the authority to license remdesivir to
third-party manufacturers to scale up production and distribution
and ensure the drug is made available to all those in need at a
reasonable price. If these agencies are unwilling to exercise this
authority, Raoul and the coalition request that the agencies assign
this authority for the states to use. The attorneys general stand
ready to ensure that drug manufacturers are licensed to meet market
demand during this public health crisis.
Joining Raoul in the letter are the attorneys general of Alaska,
American Samoa, California, Connecticut, Delaware, the District of
Columbia, Guam, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New
Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio,
Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont,
Virginia and Washington.
[Office of the Attorney General Kwame
Raoul]
![](http://archives.lincolndailynews.com/2020/Aug/05/images/ads/current/humanesociety_sda022411.png) |